 Home > Active Ingredient News > Drugs Articles > Over 1 billion U.S. dollars to help develop RNAi therapy GSK for the treatment of NASH reached a cooperation

Over 1 billion U.S. dollars to help develop RNAi therapy GSK for the treatment of NASH reached a cooperation

 Last Update: 2021-12-05
 Source: Internet
 Author: User

Tags

1 2cv 2

repaglinide 2 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Arrowhead Pharmaceuticals announced that it has reached a cooperation agreement with GlaxoSmithKline (GSK) to jointly develop and promote its research RNAi therapy ARO-HSD for the treatment of non-alcoholic steatohepatitis (NASH)
.

Currently, it is being tested in phase 1/2 clinical trials

The excessive accumulation of fat in the liver in NASH patients leads to inflammatory damage and liver fibrosis
.

At present, there are more than 100 million NASH patients in the world, and their risk of liver cirrhosis and liver cancer is significantly increased

Genetic studies have shown that a loss-of-function variant in a gene called HSD17B13 is associated with a reduced risk of chronic liver disease and a reduced risk of steatosis progressing to steatohepatitis
.

This means that reducing the expression of this gene may prevent non-alcoholic fatty liver disease from further progressing to NASH and prevent further liver fibrosis and cirrhosis in patients with NASH

ARO-HSD is an RNAi therapy designed for this target, which can inhibit the production of HSD17β13 protein expressed by this gene
.

The preliminary results of the Phase 1/2 clinical trial showed that ARO-HSD dose-dependently reduced the mRNA level of HSD17B13 in all patients.

In addition, in patients treated with ARO-HSD at doses greater than 100 mg, a decrease in liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels was observed
.

Among the 18 patients receiving treatment, 9 patients observed a decrease in liver fat levels, which was 4%-41%
.

According to the agreement, Arrowhead will receive an upfront payment of US$120 million and is eligible for development and commercialization milestone payments of more than US$1 billion
.

GSK will obtain the development and commercialization rights of ARO-HSD outside of Greater China

Reference materials:

[1] Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD.

[1] Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD.
Retrieved November 22, 2021, from https://ir.
arrowheadpharma.
com/news-releases/news-release-details/arrowhead-pharmaceuticals-enters-exclusive -license-agreement-gsk

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.